A pivotal phase 3 study of LY-03005 in major depressive disorder (MDD)
Phase of Trial: Phase III
Latest Information Update: 22 Jul 2018
Price : $35 *
At a glance
- Drugs LY 03005 (Primary)
- Indications Major depressive disorder
- Focus Registrational; Therapeutic Use
- Sponsors Luye Pharma Group
- 22 Jul 2018 Status changed from planning to recruiting, according to a Luye Pharma media release.
- 12 Jun 2018 New trial record
- 06 Jun 2018 According to a Luye Pharma media release, the company expects to begin the trial this year.